-+ 0.00%
-+ 0.00%
-+ 0.00%

Krystal Biotech wins UK MHRA approval for Vyjuvek in dystrophic epidermolysis bullosa

PUBT·05/18/2026 12:04:19
Listen to the news
Krystal Biotech wins UK MHRA approval for Vyjuvek in dystrophic epidermolysis bullosa
  • Krystal Biotech secured UK MHRA marketing authorization for VYJUVEK to treat wounds in dystrophic epidermolysis bullosa patients with COL7A1 mutations from birth.
  • The clearance includes flexible dosing options, including home administration by patients or caregivers.
  • UK launch timing hinges on completion of reimbursement procedures.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Krystal Biotech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605180800PRIMZONEFULLFEED9721913) on May 18, 2026, and is solely responsible for the information contained therein.